Research programme: cancer therapeutics - Carrick Therapeutics
Latest Information Update: 05 Dec 2022
At a glance
- Originator Carrick Therapeutics
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer